50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Democratic contraception access bill fails in US Senate

Published 06/05/2024, 06:05 AM
Updated 06/05/2024, 06:42 PM
© Reuters. A woman holds a sign in support of women's reproductive rights during a protest on International Women's Day 2023 in New York City, U.S., March 8, 2023.  REUTERS/Caitlin Ochs/ File Photo

By Moira Warburton

WASHINGTON (Reuters) -A bill to safeguard access to contraceptives failed to advance in a U.S. Senate vote on Wednesday, after congressional Democrats forced the vote in a bid to focus public attention on reproductive rights ahead of the November election.

The Right to Contraception Act, which would protect birth control access nationwide, got 51 votes in support and 39 against, but fell short of the chamber's 60-vote threshold for advancing to a full debate.

The fight over reproductive rights is a flashpoint in U.S. politics, especially since the Supreme Court's 2022 decision to overturn Roe v. Wade, the decision that had recognized a national right to abortion access.

Republican presidential candidate Donald Trump last month came under fire after comments that political rivals said suggested he would consider banning birth control, leading him to respond publicly that he would not support such a move.

Top Senate Democrat Chuck Schumer on Wednesday pointed to several states including Nevada and Virginia where Republican governors have vetoed efforts to protect legal access to contraception, saying that showed a need for federal legislation.

"We are kidding ourselves if we think the hard right will stop at overturning Roe," he said.

U.S. House of Representatives Democrats said they would attempt a legislative maneuver to force a vote on the same bill, though they faced slim chance of success in the Republican-controlled chamber.

"Republicans have a choice to make: They can put aside their MAGA ideology and join us (to) get this bill passed or they can triple down on their anti-freedom extremism in full view of the American people," No. 2 House Democrat Katherine Clark said on Tuesday.

Republican Representative Marc Molinaro, who won his district in 2022 by just 1.6%, said on Wednesday that he would cosponsor the legislation, the first Republican to do so.

Some Senate Republicans criticized the push.

"It's an election year in which a Democratic incumbent president is running behind, so a decision has been made to raise abortion to a high profile," said Republican Senator Bill Cassidy, referring to President Joe Biden. "You can't normalize a procedure where the intent is to end a life."

© Reuters. U.S. Senate Majority Leader Chuck Schumer (D-NY) speaks alongside U.S. Senator Maria Cantrell (D-WA) and U.S. Senator Ed Markey (D-MA) during a press conference following a failed vote on the “Right to Contraception Act,” in the U.S. Capitol, Washington, U.S., June 5, 2024. REUTERS/Nathan Howard

In a May Reuters/Ipsos survey of 3,934 U.S. residents 18 and older, 37% said Biden has a better approach to abortion compared to 27% who said the same about Trump ahead of a Nov. 5 election expected to be close.

Schumer said Democrats would also vote on a bill next week to protect in-vitro fertilization, which Senate Republicans previously voted against after an Alabama court made the fertility treatment used by millions of Americans to conceive effectively illegal in the state.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.